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Background: Allergic contact dermatitis (ACD) is a common skin disorder affecting an 
estimated 15-20% of the general population. The mouse model of ACD is contact 
hypersensitivity (CHS), which consists of two phases: induction and elicitation. Although 
neutrophils are required for both CHS disease phases their mechanisms of action are 
poorly understood. Neutrophils release myeloperoxidase (MPO) that through oxidation of 
biomolecules leads to cellular damage.
Objectives: This study investigated mechanisms whereby MPO contributes to CHS 
pathogenesis.
Methods: CHS was induced in mice using oxazolone (OX) as the initiating hapten applied 
to the skin. After 7 days, CHS was elicited by application of OX to the ear and disease 
severity was measured by ear thickness and vascular permeability in the ear. The role of 
MPO in the two phases of CHS was determined utilizing MPO-deficient mice and a 
specific MPO inhibitor.
Results: During the CHS induction phase MPO-deficiency lead to a reduction in IL-1 ß 
production in the skin and a subsequent reduction in migratory dendritic cells (DC) and 
effector T cells in the draining lymph node. During the elicitation phase, inhibition of MPO 
significantly reduced both ear swelling and vascular permeability.
Conclusion: MPO plays dual roles in CHS pathogenesis. In the initiation phase MPO 
promotes IL-1 ß production in the skin and activation of migratory DC that promote effector 
T cell priming. In the elicitation phase MPO drives vascular permeability contributing to 
inflammation. These results indicate that MPO it could be a potential therapeutic target for 
the treatment of ACD in humans.
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HIGHLIGHTS
• Contact hypersensitivity induction in  myeloperoxidase- 
deficient mice is characterized by lower IL-1 ß in skin 
resulting in reduced migration of dendritic cells to the 
draining lymph node and subsequented attenuated effector 
T cell priming.
• In the elicitation phase of contact hypersensitivity myeloperoxidase 
is a critical mediator driving vascular permeability.
INTRODUCTION
Allergic contact dermatitis (ACD) arises after multiple non- 
symptomatic exposures to low molecular weight substances 
called haptens affecting 20% of the general population (1, 2). 
The mouse model of ACD is contact hypersensitivity (CHS), 
which is a T cell-dependent immune response classified as a 
type four hypersensitivity reaction or delayed hypersensitivity 
response (DTH). CHS consists of two consecutive phases, 
induction and elicitation (3- 5). For induction, hapten is applied 
to bare skin, which leads to activation of keratinocytes and mast 
cells and subsequent neutrophil recruitment (3, 4). Innate immune 
cell activation in the skin was shown to lead to elevated levels of 
interleukin (IL-1ß), which contributed to dendritic cell (DC) 
activation and migration to local lymph nodes where they 
induced antigen-specific T cell differentiation towards the Th1/ 
Th17 phenotype (6- 9). During the elicitation phase, hapten is 
applied to the ears leading to activation of local keratinocytes and 
mast cells and subsequent neutrophil migration into the site (10, 
11). Increased vascular permeability leads to ear swelling, which 
facilitates migration ofantigen-specific Th1/Th17 cells into the site 
(4, 6, 9).
Neutrophils were shown to be crucial for both the induction 
and elicitation phases of CHS (12, 13). The most abundantly 
expressed protein in neutrophils is myeloperoxidase (MPO), 
which utilizes hydrogen peroxide to create hypochlorous acid 
that, in turn, oxidizes essential biomolecules leading to cell 
dysfunction and death (14- 16). In addition, MPO and its 
products have been shown to regulate the immune response in 
variable ways including lim iting DC activation (17) and 
increasing the production of proinflammatory cytokines (15, 
18, 19). The usage of MPO-deficient mice and MPO inhibitors 
has provided evidence for MPO being pathogenic in a variety of 
diseases (15, 20, 21).
We investigated the role of MPO in CHS induction and 
elicitation by utilizing active and adoptive transfer models of 
oxazolone (OX) CHS incorporating  M PO deficiency and 
inhibition. We showed that MPO promoted the induction of 
adaptive immune responses by promoting IL-1ß production 
thereby leading to DC activation and migration from skin to 
draining lymph nodes and subsequent T cell priming. In the 
elicitation phase, MPO was shown to drive vascular permeability 
contributing to local inflammation. Our data indicate that MPO 
could be a potential therapeutic target for ACD in humans.
METHODS
Mice
C57BL/6 and B6.129X1-Mpotm1Lus/J (Mpo- / - ) mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME) and 
housed  u n d er specific pathogen -free  cond itions in  the 
Translational Biomedical Research Center, Medical College of 
Wisconsin. All experiments were conducted with Institutional 
Animal Care and Use Committee approval.
Reagents and Antibodies
The MPO inhibitor tripeptide N-acetyl lysyltyrosylcysteine 
amide (KYC) was synthesized by the Protein Core Laboratory 
of Versiti Blood Research Institute. 10x HBSS, 1x HBSS, Dibutyl 
phthalate, Evans Blue, FITC (Isomer I), Formamide, OX, and 
Percoll were purchased from Sigma-Aldrich (St. Louis, MO). 
Antibodies are described in Table S1.
Flow Cytometry
Axillary and inguinal lymph nodes were isolated and single cell 
suspensions prepared. Treg were detected with the mouse Foxp3/ 
Transcription Factor Staining Buffer Set (ThermoFisher Scientific, 
Waltham, MA). IFN-g was detected by intracellular cytokine 
staining using the Intracellular Fixation & Permeabilization Buffer 
Set (ThermoFisher Scientific, Waltham, MA) (22). Samples were 
collected on a FACS Aria flow cytometer (BD Biosciences, San Jose, 
CA) and the data were analyzed using FlowJo (Tree Star, 
Ashland, OR).
CHS Induction and KYC Treatment
Mice were sensitized with 0.15 ml of 3% OX in acetone-ethanol 
(1:3) on the shaved abdomen and chest (3). Control mice were 
sham sensitized with acetone-ethanol alone. Four d later, basal 
ear thickness was measured with a micrometer (Mitutoyo, 
Tokyo, Japan), followed by challenge of on both sides of the 
ears with 1% OX (10 pl) in olive oil-acetone (1:1). Twenty-four h 
after challenge ear thickness was measured. Basal ear thickness 
was subtracted from  respective values obtained 24 h after 
challenge. Ear swelling was expressed as pm ± SE. For some 
experiments, groups of mice were i.p. injected with either PBS or 
KYC (0.03 mg/kg) twice daily starting 12 h before sensitization.
Neutrophil Depletion and T effector (Teff) 
Adoptive Cell Transfer
For adoptive cell transfer, donor C57BL/6 and Mpo-/- mice were 
sensitized with 0.15 ml 3% OX in acetone-ethanol mixture (1:3). 
Four d later, splenocyte suspensions were depleted of neutrophils 
with anti-Ly6G-biotin using the Biotin Selection Kit Easy Step from 
Stem Cell Technologies (Vancouver, BC, Canada). Depletion 
efficiency was >99%. 5 x 107 Mpo'/_ Teff cells were i.v. transferred 
to naive WT recipients and 5 x 107 WT Teff were transferred to 
naive WT and Mpo'/_ recipients. After 2 h, 1% OX in olive oil- 
acetone (1:1) was applied to the ears and ear thickness was measured 
24 h later.
Evans Blue Permeability Assay
To evaluate vascular permeability, mice were sham or 3% OX 
sensitized followed by ear challenge with 1% OX four d later and
23 h later the mice were i.v. injected with 1% Evans blue (83 pg/g 
body weight) and after 1 h a 6 mm  diameter ear punch biopsy was 
collected and placed into 0.5 ml of formamide. The ear tissue was 
incubated for 18 h at 37°C and after centrifugation, the optical 
density (OD) of Evens blue in the supernatant was read at 565 nm 
and a standard curve was used to determine the EB concentration.
Neutrophil Isolation
Neutrophils were isolated at room  tem perature from  bone 
marrow (BM) extracted from the femurs and tibiae of WT 
mice. Total BM cells were resuspended in 45% Percoll that 
layered on a Percoll gradient of 66%, 60%, 55%, and 50%. The 
cells were centrifuged at 2800 rpm  for 30 min without using the 
break. The bottom band of cells between the 60% and 66% layers 
were collected, resuspended in 10 ml HBSS with 0.1% BSA, 
centrifuged at 1200 rpm  for 10 min and washed twice with HBSS. 
Cell purity was determined by flow cytometry and 96% of the 
CD11b+ cells were neutrophils (CD11b+Ly6C+Gr1+).
Electric Cell-Substrate 
Impedance Sensing
Using the ECIS Z System (Applied BioPhysics, Inc. Troy NY) a 
8W10E+ array was stabilized and coated with 200 pl of 0.1% gelatin 
for 30 min at 37° C prior to seeding with bEnd3 cell line cells at
80.000 per well. The cells were cultured until capacitance (nF) at
64.000 Hz reached the range from 1 to 5nF. For the co-culture assay 
the growth medium was exchanged with HBSS (Ca2+, Mg2+) with 
5.5 mM glucose. 0.2 x 106 purified neutrophils were stimulated with 
2 pM PMA for 12 min in HBSS. Activated neutrophils were treated 
with 25 pM KYC for 10 min. Neutrophils were added to the 
endothelial monolayer and impedance was collected at 4000 Hz 
every 15 s for up to 4.5 h.
FITC-Induced Cutaneous DC 
Migration Assay
To evaluate the migration of DC from skin to draining lymph 
nodes, the shaved abdomen and chest were painted with 100 pl 
of 0.5% FITC isomer I dissolved in a 1:1 (v/v) acetone/dibutyl 
phthalate mixture (23). Six h\ later, draining lymph nodes were 
collected and the absolute num ber of FITC+ DC and their 
percentage am ong B220-FITC+ cells was determ ined  by 
flow cytometry.
ELISA
To evaluate IL-1ß concentration in sensitized skin, WT and Mpo'/_ 
were sensitized with 0.15 ml of 3% OX in acetone-ethanol (1:3) on 
the shaved abdomen and chest. Control mice were sham sensitized 
with acetone-ethanol alone. After 6 h, abdominal skin was excised 
and 6 mm  biopsy punches were collected to 200 pl of modified 
RIPA buffer (10 mM Tris-HCL ph=7.4, 150 mM NaCl, 0.25%% 
Triton X) with Protease Inhibitor Cocktail (Sigma-Aldrich, St. 
Louis, MO). The samples were homogenized and the supernatants 
were transferred to a new tube and the beads were washed with 50 
pl buffer, followed by centrifugation (15 min, 4° C, 14000 x g). The
IL-1ß concentration was determined using the Mouse IL-1ß/IL- 
1F2 DuoSet ELISA (R&D Systems, Minneapolis, MN) according 
to manufacture instructions.
Statistical Analysis
Normally distributed data were analyzed using ANOVA followed 
by Bonferroni’s Multiple Comparison Test for com parison 
between m ultiple groups. For two-group com parison, the 
unpaired t-test was used. Data are presented as mean values ± 
SEM and a p-value <0.05 was considered significant using 
GraphPad Prism (San Diego, CA).
RESULTS 
Attenuation of the CHS Response 
in MPO-Deficient Mice
Here, we investigated MPO as an neutrophil effector molecule in 
CHS using ear swelling to quantitate disease penetrance. There 
was no difference in ear thickness between WT and Mpo'/_ mice 
following sham sensitization and OX challenge to the ear (Figure 
1A). However, following sensitization with OX, WT mice 
exhibited a significant increase in ear thickness 24 h after OX 
challenge (Figure 1A). Although ear swelling increased in Mpo'/_ 
mice following sensitization and challenge, it was significantly 
lower than in WT mice (Figure 1A).
To confirm a role for MPO in the pathogenesis of CHS, we 
utilized KYC, a specific inhibitor ofM PO toxic oxidant production 
that we developed (24). KYC (0.03 mg/kg) was i.v. administered 
every 12 h starting at -12 h. Following OX challenge, MPO 
inhibition with KYC significantly reduced, but did not prevent 
ear swelling (Figure 1B). The identical result was obtained in mice 
in which KYC administration was initiated 1 day following 
sensitization (data not shown). The optimal dosage of KYC 
(0.03 mg/kg) was experimentally determined in a dose-response 
study and was consistent with our previous studies (25, 26).
MPO Enhances the Induction of the 
Adaptive Immune Response in CHS
The reduction in ear swelling in Mpo'/_ (Figure 1A) and KYC- 
treated (Figure 1B) mice indicated that MPO could potentially 
promote efficient T cell priming. Thus, to establish the impact of 
MPO on the induction of the adaptive immune response to OX, 
we quantitated T cell subsets in the skin draining lymph nodes 
four d after sensitization. We found no difference in the absolute 
number of CD4 (Figure 2A) or CD8 T cells (Figure 2B) in WT 
as compared to Mpo'/_ mice that were sham sensitized. In 
contrast, there as a significant reduction in the absolute 
number of both CD4 (Figure 2A) and CD8 (Figure 2B) T 
cells in M po'/_ OX sensitized mice. A representative flow 
cytometry plot illustrating the gating strategy for all groups is 
shown in Figure 2C. Because there was a significant decrease in 
the absolute number of CD4 and CD8 T cells in Mpo'/_ CHS 
mice, we next determined whether this was due to an attenuation 
of T cell priming. First, we examined CD62L, a marker of naive
FIGURE 1 | MPO-deficiency and inhibition reduced inflammation in the OX CHS model. Mice were sham (WT, Mpov~) or OX (3%) sensitized and four d later were 
ear challenged with OX (1%). (A) Ear thickness was measured with a caliper 24 h later. (B) Mice were i.v. administered 0.03 mg/kg KYC every 12 h starting at -12 h 
prior to sensitization until the end of the study. Each symbol represents one ear with data from three separate experiments shown. ***p<0.001, ns, not significant.
FIGURE 2 | MPO-deficiency reduces the induction of the adaptive immune response. WT and Mpo'/_ mice were OX (3%) or sham immunized. After four d lymph 
nodes cells were collected, and single cell suspensions were stained with fluorochrome-conjugated antibodies and analyzed by flow cytometry and the absolute cell 
number of CD4+ T cells (A), CD8+ T cells (B), CD4+CD62L- T cells (D), CD8+CD62L- T cells (E), CD4+IFN-g+ T cells (G), and CD8+IFN-g+ T cells (H) was determined. 
Representative flow cytometry gating is shown for CD3-gated CD4 and CD8 T cells (C), CD8+CD62L- T cells (F), and CD8+IFN-g+ T cells (I). Each symbol 
represents data from one mouse with data from two to three independent experiments shown. *p<0.05; **p<0.01; ***p<0.001; ns, not significant.
T cells that is shed upon their activation (27). In both CD4 
(Figure 2D) and CD8 (Figure 2E) Teff cells a significant decrease 
in CD62L- cells was observed in sensitized Mpo-/- mice as 
compared to WT mice. A representative flow cytometry gating 
strategy for all groups is shown in Figure 2F. Similar results were 
obtained when IFN-g producing CD4 and CD8 Teff were 
quantitated (Figures 2 G -I). These results suggest that MPO
affects the magnitude of the adaptive immune response, but does 
not alter the nature of naive T cell priming.
MPO-Deficiency Does Not Impact 
Lymphocyte Proliferation
To determine whether the reduction in Teff cells was due to 
reduced proliferation, we quantitated the number and percentage
of Ki-67+ T cells ( 28). For both CD4 (Figure 3A) and CD8 ( Figure 
3B) T cells there was no significant difference in the absolute 
number or percentage of Ki-67+ cells between WT and M p o -/- 
sham sensitized mice. While there was a significant decrease in the 
absolute number of Ki-67+ CD4 T cells in M p o -/- mice as compared 
to WT mice OX sensitized mice, the percentage of cells undergoing 
proliferation was not different (Figure 3A). For CD8 T cells, there 
was not a significant difference in the absolute num ber nor 
percentage of cells undergoing proliferation (Figure 3B). Since 
the extent of the adaptive immune response is controlled by 
CD4+Foxp3+ T regulatory cells (29- 31), we next determined 
whether their numbers were increased in M p o -/- mice. The 
absolute num ber and percentage of Treg was not different 
between sham sensitized WT and M p o -/- mice (Figure 3C). In 
sensitized mice, the absolute number of Treg was reduced in M p o -/- 
mice without a difference in the percentage of Treg (Figure 3C). 
Representative flow cytometry gating strategies for all groups are 
shown (Figures 3A -C). These cumulative data indicate that the 
reduced adaptive immune response in M p o -/- mice is not due to 
changes in the level of CD4 and CD8 T cell proliferation or 
increased Treg numbers.
MPO Enhances DC Migration to the 
Draining Lymph Nodes
Because MPO-deficiency led to a decrease in the number of 
primed T cells in the draining lymph node in CHS, we next 
determined whether this was correlated to a similar reduction in 
DC cell numbers. W hen we quantitated the absolute number of 
migratory DC (B220-CD11c+MHCII+) (23) in the draining 
lymph nodes four d after OX sensitization, we found that 
M p o -/- mice had a significant reduction in the absolute number 
of DC, but the percentage of DC was not changed (Figure 4A). 
This finding was not due to reduced numbers or the percentage 
of migratory DC in the sham control mice (Figure 4A). To 
confirm that MPO-deficiency specifically impacted migratory 
DC, mice were skin painted with FITC and the number of FITC+ 
DC in the draining lymph node was quantitated 24 h later. In the 
absence of FITC skin painting, FITC+ migratory DC were not 
detectable. In FITC painted mice, there was a significant decrease 
in the absolute number and percentage of FITC+ DC (Figure 
4B). Representative flow cytometry gating for all groups is shown 
(Figures 4A, B). These data suggest that T cell priming is
FIGURE 3 | MPO-deficiency does not influence CD4 and CD8 T cell proliferation or Treg numbers in the draining lymph node during induction of CHS. WT and 
Mpov~ mice were OX (3%) or sham immunized. After four d lymph nodes cells were collected, and single cell suspensions were stained with fluorochrome- 
conjugated antibodies and analyzed by flow cytometry. The absolute cell number and frequency of Ki-67+TCRß+CD4+ T cells (A), Ki-67+TCRß+CD8+ T cells (B) and 
TCRß+CD4+Foxp3+ Treg (C) was determined by flow cytometry. Each symbol represents data from one mouse with data from two to three separate experiments 
shown. Representative flow cytometry gating for each cell type is shown in the right column (A -C ). **p<0.01; ***p<0.001; ns, not significant.
reduced in M p o -/- mice as the result of fewer skin DC migrating 
to the draining lymph node. Representative flow cytometry 
gating is shown (Figures 4A, B).
MPO Deficiency Hampers IL-1 ß 
Production in the Skin in Response to 
OX Sensitization
To investigate the mechanism of reduced migratory DC in the 
draining lym ph nodes IL-1 ß production  in the skin was 
measured because of its role in promoting DC migration (7, 8). 
Following sham sensitization, IL-ß in the skin was significantly 
higher in Mpo-/- mice as compared to WT (Figure 5). Six h 
following OX challenge in sensitized mice the level of IL-1 ß in 
the skin significantly increased in WT, but was unchanged in 
Mpo-/- mice (Figure 5). These data indicate that MPO is essential 
for the generation of active IL-1 ß expression in the skin that 
facilitates the activation and subsequent migration of DC from 
the skin to the draining lymph node to initiate T cell priming to 
the sensitizing hapten.
Attenuation of the CHS Response 
in MPO-Deficient Mice
Here, we investigated MPO as an neutrophil effector molecule in 
the CHS elicitation as a driver of vascular permeability. This 
question was first addressed using ECIS, which is an in  v it ro  
system to measure cell behavior of adherent cell layers (32). ECIS 
was used to quantitate neutrophil-derived MPO disruption of an 
endothelial cell monolayer using bEnd3 cells (33- 35). Electric
current was applied and following equilibration, there was no 
change in the electrical potential for greater than four h in 
medium or after addition of resting neutrophils (Figure 6A). 
In contrast, neutrophils activated with PMA induced a sharp 
increase in impedance, that returned to baseline after ~1 h and 
then steadily decreased over two h (Figure 6A). The drop below 
baseline indicated a loss of barrier function. Inclusion of KYC 
with the PMA activated neutrophils completely inhibited the loss 
of barrier function (Figure 6A). The spike in increased barrier 
integrity was evident in every sample containing PMA (Figure 
6A). Quantitation of the 2.5 h timepoint showed a significant 
reduction in impedance when KYC was added to PMA activated 
neutrophils (Figure 6B).
We next determined whether MPO contributes to vascular 
permeability in CHS by measuring vascular leakage with Evans 
blue. In sham sensitized mice, there was no difference in vascular 
perm eability between W T and M po-/- mice (F igure 6C ). 
Sensitized WT mice exhibited a significant increase in vascular 
leakage, while Mpo-/- mice did not (Figure 6C). To confirm a role 
for MPO, we treated mice with KYC every 12 h from day -0.5, 
which led to a significant inhibition of vascular leakage (Figure 
6D). In Figure 6E, images are shown of mouse ears that were 
sham sensitized followed by OX challenge on the ear 4 d later 
that exhibit no obvious inflammation as compared to mice 
receiving both OX sensitization and challenge, which exhibited 
dilated blood vessels (arrows) and evidence of inflammation as 
in d ic a te d  by in c re ase d  red n ess  (c irc le) (F ig u re  6E ). 
Inflammation in mice treated with KYC to inhibit MPO was
FIGURE 4 | MPO-deficiency reduces DC migration from skin to the draining lymph nodes during CHS. WT and Mpo_/" mice were OX (3%) or sham immunized. 
After 4 days, skin-draining auxiliary lymph nodes were collected, and single cell suspensions were stained with fluorochrome-conjugated antibodies and analyzed by 
flow cytometry and the absolute cell number and percentage of B220-CD11c+ MHC class II+ DC (A) was determined. WT and Mpo_/" mice were skin painted with 
0.5% FITC and 6 h later the absolute number and percentage of FITC+ DC among B220-FITC+ cells was determined (B). Each symbol represents data from one 
mouse with data from three (A) separate experiments shown or is one representative experiment of two (B). Representative flow cytometry gating is shown on the 
right for each analysis. (A, B). *p<0.05; ***p<0.001; ns, not significant.
FIGURE 5 | MPO-deficiency reduces IL-1 ß levels in skin biopsies. WT and 
Mpov~ mice were OX (3%) or sham immunized. After 6 h skin biopsies were 
collected and IL-1 ß levels were quantitated by ELISA. Each symbol 
represents data from one mouse with data from two separate experiments 
shown. *p<0.05; ***p<0.001; ns, not significant.
reduced as shown by decreased blood vessel dilation and redness 
(Figure 6E).
To confirm the critical role for neutrophil-derived MPO in 
the elicitation phase of CHS, we performed an adoptive transfer 
experiment in which OX primed Teff cells from WT or Mpo-/- 
donors were depleted of neutrophils prior to transfer into naive 
recipients, which were subsequently ear challenged with OX. Teff 
cells from both WT and Mpo-/- mice transferred into WT donors 
induced similar levels of ear swelling (Figure 6F) and vascular 
permeability (Figure 6G). In contrast, when neutrophil depleted 
Teff from WT mice were transferred into Mpo-/- recipients, there 
was a significant decrease the level of ear swelling (Figure 6F) 
with no accompanied vascular permeability (Figure 6G). These 
data indicate that neutrophils drive the elicitation phase by 
release of MPO that promotes vascular permeability.
DISCUSSION
In this study, we investigated whether neutrophil-derived MPO 
plays a role in the induction and/or elicitation phases of ACD 
using the OX CHS mouse model. Here, we demonstrated that 
CHS was attenuated when MPO was deficient or inhibited and 
demonstrated that MPO plays a role during both the induction 
and elicitation phases of CHS. In the induction phase, we showed 
that MPO was important for optimal migration of DC from the 
skin to the draining lymph node where they primed naive T cells 
to the OX hapten. In the elicitation phase, we found that MPO 
was essential for vascular permeability leading to ear swelling. 
Our findings are outlined in graphic form in Figure 7. These 
cumulative data suggest that neutrophils are a mediator of ACD 
through MPO release.
Although MPO is well characterized as a microbiocidal (36), 
it is now known to be pathogenic in a variety of diseases. 
Activation of neutrophils and subsequent MPO release also 
occurs in response to endogenous inflammatory stimuli even 
in the absence of infection (37), which is consistent with our 
previous studies demonstrating a pathogenic role for MPO in 
mouse models of multiple sclerosis, stroke and sickle cell disease 
(25, 26, 38). The exact mechanisms whereby MPO is pathogenic 
is not well understood (15, 36, 37, 39, 40). A molecular footprint 
of MPO are proteins containing chlorinated tyrosine (Cl-Tyr), 
which along with an additional MPO halogenation product 3- 
bromotyrosine, were reduced in MPO-deficient mice with sepsis 
(41). MPO-derived products not only induce oxidative stress but 
have also been shown to increase pro-inflammatory cytokine 
production (18, 42). Of particular interest is IL-1ß, whose 
production by keratinocytes in CHS was shown to promote 
DC emigration from skin to the draining lymph node (7- 9). In 
addition, IL-1 ß was shown to be rapidly upregulated in 
Langerhans cells following hapten application (43). The finding 
that antibody neutralization of IL-1 ß prior to sensitization 
abrogated CHS provides evidence of its pathogenic role (44). 
This was further supported by an impairment in CHS in mice 
deficient in inflammasome components required to generate 
active IL-1 ß (45). Our finding that Mpo-/- mice with CHS 
failed to upregulate IL-1 ß in the skin provides strong evidence 
that MPO is a critical factor promoting IL-1 ß transcription and/ 
or activation by the inflammasome (46).
We showed that the absolute number and percentage of 
migratory DC was reduced in Mpo-/- mice with CHS, which is 
consistent with studies showing that neutrophils activate and 
induce DC migration to local lymph nodes during microbial 
infection, neuro-inflammation, as well as CHS resulting in 
activated T cell production of IL-17 and IFN-g (12, 47- 50). 
While these studies did not investigate MPO as a mechanism, 
others showed that MPO was measurable in the draining lymph 
node several hours after OVA/LPS injection that was correlated 
to a reduction in the expression of the lymph node homing 
receptor CCR7 on DC (17). However, the former study used LPS 
and not a hapten and did not focus on cutaneous DC and their 
migratory potential. It is well known that epidermis and dermis 
contain differential populations of antigen presenting cells. 
Langerhans cells are found in the epidermis, while the dermis 
contains two populations of DC with variable abilities to exhibit 
activation or inhibitory functions in CHS (51), which implies 
that MPO could have a differential impact on DC function 
depending on their phenotype and location.
Following hapten  application to the skin, particularly 
Langerhans cells, become activated and emigrate to the draining 
lymph node, where they activate antigen-specific T cells (8, 52). 
Thus, the direct consequence of reduced DC migration to the 
draining lymph node would be reduced numbers of antigen 
presenting cells and abrogated T cell priming. Our findings of 
reduced numbers of CD4 and CD8 Teff cells in Mpo-/- mice with 
CHS as compared to WT are consistent with the reduced numbers 
of migratory DC. Of interest is that the nature of the immune 
response was not altered in Mpo-/- mice as shown by no difference
FIGURE 6 | MPO supports the elicitation of CHS by increasing vascular permeability. (A, B) Confluent monolayers of bEnd3 cells were established on collagen-coated gold 
electrodes and impendence measurements at 4 kHz were conducted. (A) After establishment of the steady state level of impendence, impendence was measured in 
medium alone (control) or in the presence of unstimulated neutrophils (neut), PMA (20 mM), PMA + KYC (25 mM), PMA + neutrophils, or PMA + neutrophils + KYC. (B) At the 
2.5 h time point impendence level was quantitated for each condition. The experiment shown is representative of two. C-E) Mice were sham (WT, Mpo~/~) or OX (3%) 
sensitized and 4 days later were ear challenged with OX (1 %). Vascular permeability was measured 24 h later by Evans blue leakage from the vascular into the tissue 60 min 
after i.v. administration (C, D). (D, E) Mice were i.v. administered 0.03 mg/kg KYC every 12 h starting at -12 h prior to sensitization until the end of the study. Each symbol 
represents one ear with data from three separate experiments shown. (E) Twenty-four hours after OX challenge mouse ears were photographed using Zeiss Lumar.V12 
stereoscope at 6.4x. Blood vessels are indicated by arrows and areas exhibiting inflammation are circled. The top panels show the dorsal side and the bottom panels the 
ventral side of the ear. (F, G) WT or Mpo~/~ mice were OX (3%) immunized and four d later Teff cells were isolated and depleted of neutrophils and adoptively transferred into 
WT or Mpo~/~ recipients that were subsequently ear challenged with OX (1%). Twenty-four h later ear thickness (F) and vascular permeability (G) was measured. Each symbol 
represents one ear with data from one representative experiment of two shown. *p<0.05; **p<0.01; ***p<0.001; ns, not significant.
in the percentage of CD4 and CD8 T cell undergoing proliferation 
or producing IFN-g production. In addition, while the absolute 
number of Treg was reduced their proportion was not, indicating 
direct immune suppression is not likely the mechanism for the
reduced numbers of T cells in Mpo-/- mice with CHS. These data 
indicate that MPO inhibition could be used to modulate the extent 
of the adaptive immune response without compromising its 
protective functions.
FIGURE 7 | Model outlining the role of MPO in the induction and elicitation phases of CHS. (A) For induction of CHS oxazolone (OX) is applied to the skin, which 
results in migration of neutrophils into the skin and release of MPO and subsequent induction of IL-1 ß production within the skin. Skin resident dendritic cells (DC) 
take up Ox and become activated that is facilitated by IL-1 ß. The activated DC migrate to the draining lymph node. IL-1 ß is decreased in Mpov~ mice resulting in a 
reduction in the number of activated DC. (B) Once in the draining lymph node, DC interact with naive T cells (T) and present Ox via MHC class I and II to activate 
antigen-specific CD4+ and CD8+ T cells, respectively. Due to a reduction of activated DC reaching the draining lymph node in Mpo'/_ mice, T cell priming is reduced. 
(C) For the elicitation of CHS, Ox is applied to the ears, which results in the migration of effector T cells and neutrophils into the ears. Neutrophils release MPO (C), 
which catalyzes the production of free radicals and oxidants that drive vascular permeability leading to swelling as indicated by an increase in the thickness of the 
ears (D). (D) In the absence of MPO, the production of free radicals and oxidants is reduced thereby reducing vascular permeability and ear swelling.
(A-D) Treatment with KYC by inhibiting MPO activity would result in similar biological outcomes as those observed in Mpo'/_ mice.
Our finding that adoptive transfer of WT neutrophils into 
MPO-deficient mice resulted in a significantly attenuated disease 
is consistent with other studies showing a crucial role for 
neutrophils during elicitation. The CHS response was shown to 
be inhibited by the depletion of neutrophils prior to CHS 
elicitation (12, 53). Similarly, the adoptive transfer of WT 
effector cells to neutrophil-depleted or neutrophil deficient 
animals abrogated CHS ear swelling (12). Ear swelling is 
associated with an increase in vascular permeability, which was 
shown to be mediated by neutrophils in many pathological 
conditions such as neurological diseases, sepsis and ischemia- 
reperfusion (54, 55). We also showed that MPO is essential for 
vascular permeability induced during the CHS elicitation phase. 
ECIS in vitro studies provided evidence that MPO alone is 
sufficient to induce vascular permeability, which is consistent 
with previous findings (35). While these cumulative findings 
indicate that neutrophil-derived MPO is a potent inducer of 
vascular permeability, the precise mechanism(s) evoked in vivo is 
not known.
CONCLUSION
In this study, we provide evidence that MPO is an important 
neutrophil effector molecule in CHS. We found that during hapten 
sensitization MPO is required for both optimal IL-1 ß production 
in the skin and DC activation and emigration to the draining 
lymph node thereby regulating the magnitude of the adaptive 
immune response. We also found a role for MPO in the elicitation 
phase in which it plays an essential role in induction of vascular
permeability. These cumulative findings indicate the MPO is a 
potential therapeutic target for the treatment of persistent ACD in 
humans. Given that MPO is a potent bactericidal (36), inhibition 
of MPO systemically may lead to an increase in infections. 
However, several studies have shown that the majority of MPO- 
insufficient humans are asymptomatic, although the risk of severe 
infections was higher (56- 58). A benefit of inhibiting MPO with 
the tripeptide KYC or a similar drug is that its effects would be 
quickly reversed upon drug withdrawal.
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